• LAST PRICE
    4.2500
  • TODAY'S CHANGE (%)
    Trending Up0.0600 (1.4320%)
  • Bid / Lots
    4.2500/ 6
  • Ask / Lots
    4.8800/ 10
  • Open / Previous Close
    4.1600 / 4.1900
  • Day Range
    Low 4.1300
    High 4.3500
  • 52 Week Range
    Low 3.8900
    High 9.1000
  • Volume
    70,165
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4.19
TimeVolumeEPRX
10:46 ET10004.14
11:04 ET2004.15
11:15 ET32004.15
11:20 ET9004.15
11:31 ET30004.14
12:23 ET50004.15
12:43 ET31004.15
12:56 ET2004.15
01:10 ET6004.13
01:12 ET1004.18
01:14 ET7004.21
01:39 ET99004.29
01:42 ET20004.3
02:00 ET150004.3
03:20 ET42004.35
03:21 ET196004.22
03:57 ET14004.25
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaEPRX
Eupraxia Pharmaceuticals Inc
148.9M
-3.1x
---
CanadaACOG
Alpha Cognition Inc
116.8M
-4.0x
---
CanadaZEN
Zentek Ltd
161.3M
-13.5x
---
CanadaNGEN
NervGen Pharma Corp
130.9M
-6.6x
---
CanadaARCH
Arch Biopartners Inc
138.1M
-71.8x
---
CanadaCRDL
Cardiol Therapeutics Inc
170.4M
-5.6x
---
As of 2024-03-29

Company Information

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company’s principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.

Contact Information

Headquarters
201-2067 Cadboro Bay Rd.VICTORIA, BC, Canada V8R 5G4
Phone
250-590-3968
Fax
250-590-2588

Executives

Non-Executive Independent Chairman of the Board
Simon Pimstone
President, Chief Financial Officer
Bruce Cousins
Chief Executive Officer, Director
James Helliwell
Chief Scientific Officer
Amanda Malone
Chief Business Officer
Paul Brennan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$151.1M
Revenue (TTM)
$0.00
Shares Outstanding
35.5M
Eupraxia Pharmaceuticals Inc does not pay a dividend.
Beta
---
EPS
$-1.39
Book Value
$0.60
P/E Ratio
-3.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.